T0	Participants 33 101	renal transplant recipients with tacrolimus-based immunosuppression.
T1	Participants 301 329	renal transplant recipients.
T2	Participants 394 621	15 centers in France and 1 center in Belgium; 309 patients were randomized to receive either induction therapy with ATG (n=151) followed by initiation of tacrolimus on day 9 or immediate tacrolimus-based triple therapy (n=158).